Prescribing information

 

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults, adolescents and children from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation (CRP and/or MRI evidence) in adults who have responded inadequately to non-steroidal anti-inflammatory drugs.

Hear more from other professionals around the UK on how they are using You First in real-life clinical practice.

 

Click here for Cosentyx (secukinumab) prescribing information

You First: The benefits of a bespoke patient support programme

Listen to Nurse Manager Jenny Fleming, Associate Professor in Inflammatory Skin Diseases Miriam Wittmann and Hospital Pharmacist Anusha Patel discuss the benefits of You First as a bespoke patient support programme.

Click here for Cosentyx (secukinumab) prescribing information

You First – a Healthcare Professional’s Experience

Hear from Clinical Nurse Specialist Toni Dorman on her experiences using You First in clinical practice.

 

CRP, c-reactive protein; DMARD, disease modifying anti-rheumatic drug; MRI, magnetic resonance imaging; MTX, methotrexate.

Rate this content: 
No votes yet
UK | October 2021 | 154485
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]